Cargando…

New Roles of Glycosaminoglycans in α-Synuclein Aggregation in a Cellular Model of Parkinson Disease

The causes of Parkinson disease (PD) remain mysterious, although some evidence supports mitochondrial dysfunctions and α-synuclein accumulation in Lewy bodies as major events. The abnormal accumulation of α-synuclein has been associated with a deficiency in the ubiquitin-proteasome system and the au...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lehri-Boufala, Sonia, Ouidja, Mohand-Ouidir, Barbier-Chassefière, Véronique, Hénault, Emilie, Raisman-Vozari, Rita, Garrigue-Antar, Laure, Papy-Garcia, Dulce, Morin, Christophe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4305359/ https://www.ncbi.nlm.nih.gov/pubmed/25617759 http://dx.doi.org/10.1371/journal.pone.0116641

Ejemplares similares

Glycosaminoglycans from Alzheimer’s disease hippocampus have altered capacities to bind and regulate growth factors activities and to bind tau
por: Huynh, Minh Bao, et al.
Publicado: (2019)

Rifampicin and Its Derivative Rifampicin Quinone Reduce Microglial Inflammatory Responses and Neurodegeneration Induced In Vitro by α-Synuclein Fibrillary Aggregates
por: Acuña, Leonardo, et al.
Publicado: (2019)

Rifampicin quinone pretreatment improves neuronal survival by modulating microglia inflammation induced by α-synuclein
por: Acuña, Leonardo, et al.
Publicado: (2020)

3-O-sulfated heparan sulfate interactors target synaptic adhesion molecules from neonatal mouse brain and inhibit neural activity and synaptogenesis in vitro
por: Maïza, Auriane, et al.
Publicado: (2020)

CMT-3 targets different α-synuclein aggregates mitigating their toxic and inflammogenic effects
por: González-Lizárraga, Florencia, et al.
Publicado: (2020)

Repurposing doxycycline for synucleinopathies: remodelling of α-synuclein oligomers towards non-toxic parallel beta-sheet structured species
por: González-Lizárraga, Florencia, et al.
Publicado: (2017)

Monitoring α-synuclein aggregation
por: Estaun-Panzano, Juan, et al.
Publicado: (2023)

Alpha-Synuclein Aggregation in Parkinson's Disease
por: Srinivasan, E., et al.
Publicado: (2021)

Protective Effects of a synthetic glycosaminoglycan mimetic (OTR4132) in a rat immunotoxic lesion model of septohippocampal cholinergic degeneration
por: Pereira, Patricia Marques, et al.
Publicado: (2022)

The Effect of Glycosaminoglycans (GAGs) on Amyloid Aggregation and Toxicity
por: Iannuzzi, Clara, et al.
Publicado: (2015)

Models of α-synuclein aggregation in Parkinson’s disease
por: Giráldez-Pérez, Rosa María, et al.
Publicado: (2014)

Immunotherapy in Parkinson’s Disease: Micromanaging Alpha-Synuclein Aggregation
por: George, Sonia, et al.
Publicado: (2015)

The Pesticide Chlordecone Promotes Parkinsonism-like Neurodegeneration with Tau Lesions in Midbrain Cultures and C. elegans Worms
por: Parrales-Macias, Valeria, et al.
Publicado: (2023)

The Aggregation of Huntingtin and α-Synuclein
por: Chánez-Cárdenas, María Elena, et al.
Publicado: (2012)

Fasudil attenuates aggregation of α-synuclein in models of Parkinson’s disease
por: Tatenhorst, Lars, et al.
Publicado: (2016)

Chemicals Possessing a Neurotrophin-Like Activity on Dopaminergic Neurons in Primary Culture
por: Schmidt, Fanny, et al.
Publicado: (2009)

Doxycycline Interferes With Tau Aggregation and Reduces Its Neuronal Toxicity
por: Medina, Luciana, et al.
Publicado: (2021)

Contributive Role of TNF-α to L-DOPA-Induced Dyskinesia in a Unilateral 6-OHDA Lesion Model of Parkinson’s Disease
por: dos Santos Pereira, Maurício, et al.
Publicado: (2021)

Glycosaminoglycans and Glycosaminoglycan Mimetics in Cancer and Inflammation
por: Morla, Shravan
Publicado: (2019)

Cervical skin denervation associates with alpha‐synuclein aggregates in Parkinson disease
por: Melli, Giorgia, et al.
Publicado: (2018)

Parkinson’s Disease: A Nanotheranostic Approach Targeting Alpha-Synuclein Aggregation
por: Zoey, Fong LaiGuan, et al.
Publicado: (2021)

Silica Nanoparticles Promote α-Synuclein Aggregation and Parkinson’s Disease Pathology
por: Yuan, Xin, et al.
Publicado: (2022)

Small soluble α-synuclein aggregates are the toxic species in Parkinson’s disease
por: Emin, Derya, et al.
Publicado: (2022)

Targeted degradation of ⍺-synuclein aggregates in Parkinson’s disease using the AUTOTAC technology
por: Lee, Jihoon, et al.
Publicado: (2023)

SUMOylation of Alpha-Synuclein Influences on Alpha-Synuclein Aggregation Induced by Methamphetamine
por: Zhu, Lin-nan, et al.
Publicado: (2018)

Acceleration of α-Synuclein Aggregation by Exosomes
por: Grey, Marie, et al.
Publicado: (2015)

Aggregation and neurotoxicity of recombinant α-synuclein aggregates initiated by dimerization
por: Roostaee, Alireza, et al.
Publicado: (2013)

Unveiling a Selective Mechanism for the Inhibition of α-Synuclein Aggregation by β-Synuclein
por: Leitao, Andre, et al.
Publicado: (2018)

Synuclein Family Members Prevent Membrane Damage by Counteracting α-Synuclein Aggregation
por: Scheibe, Christian, et al.
Publicado: (2021)

Characterization of extracts from Papaver rhoeas and potential valorization of these extracts in dyeing applications
por: BOUSSOUM, Mohand Ouidir, et al.
Publicado: (2021)

The Role of Alpha-Synuclein Oligomerization and Aggregation in Cellular and Animal Models of Parkinson’s Disease
por: Wan, Oi Wan, et al.
Publicado: (2012)

Catecholamines and Neurodegeneration in Parkinson’s Disease—From Diagnostic Marker to Aggregations of α-Synuclein
por: Sawada, Hideyuki, et al.
Publicado: (2013)

Blood Plasma of Patients with Parkinson's Disease Increases Alpha-Synuclein Aggregation and Neurotoxicity
por: Wang, Peng, et al.
Publicado: (2016)

Plant Extracts and Phytochemicals Targeting α-Synuclein Aggregation in Parkinson's Disease Models
por: Javed, Hayate, et al.
Publicado: (2019)

Differential Aggregation and Phosphorylation of Alpha Synuclein in Membrane Compartments Associated With Parkinson Disease
por: Canerina-Amaro, Ana, et al.
Publicado: (2019)

Disease-Associated α-Synuclein Aggregates as Biomarkers of Parkinson Disease Clinical Stage
por: Majbour, Nour, et al.
Publicado: (2022)

Dynamics of a model for the degradation mechanism of aggregated α-synuclein in Parkinson's disease
por: Yang, Bojie, et al.
Publicado: (2023)

Correction: Targeted degradation of ⍺-synuclein aggregates in Parkinson’s disease using the AUTOTAC technology
por: Lee, Jihoon, et al.
Publicado: (2023)

Anionic Nanoplastic Contaminants Promote Parkinson’s Disease-Associated α-Synuclein Aggregation
por: Liu, Zhiyong, et al.
Publicado: (2023)

Anionic nanoplastic contaminants promote Parkinson’s disease–associated α-synuclein aggregation
por: Liu, Zhiyong, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_fbmejstsk8i6dd8ekv1c65gij6